Pharmacotherapy for inherited colorectal cancer

Bibliography

• Sporn MB, Dunlop NM, Newton DL, Smith JM. Prevention of chemical carcinogenesis by vitamin A and its synthetic analogs (retinoids). Fed Proc 1976;35(6):1332-8
   PubMedGoogle Scholar
• Parkin DM, Bray F, Ferlay J, Pisani P. Estimating the world cancer burden: Globocan 2000. Int J Cancer 2001;94(2):153-6
   PubMed Web of Science ®Google Scholar
• Winawer SJ, Zauber AG, Ho MN, Prevention of colorectal cancer by colonoscopic polypectomy. The National Polyp Study Workgroup. N Engl J Med 1993;329(27):1977-81
   PubMed Web of Science ®Google Scholar
• Church J, Simmang C. Practice parameters for the treatment of patients with dominantly inherited colorectal cancer (familial adenomatous polyposis and hereditary nonpolyposis colorectal cancer). Dis Colon Rectum 2003;46(8):1001-12
   PubMed Web of Science ®Google Scholar
• Desch CE, Benson AB III, Somerfield MR, Colorectal cancer surveillance: 2005 update of an American Society of Clinical Oncology practice guideline. J Clin Oncol 2005;23(33):8512-9
   PubMed Web of Science ®Google Scholar
• Levin B, Barthel JS, Burt RW, Colorectal Cancer Screening Clinical Practice Guidelines. J Natl Compr Canc Netw 2006;4(4):384-420
   PubMedGoogle Scholar
• Lynch PM. New issues in genetic counseling of hereditary colon cancer. Clin Cancer Res 2007;13(22 Pt 2):6857s-61s
   Web of Science ®Google Scholar
• Smith RA, Cokkinides V, Eyre HJ. American Cancer Society guidelines for the early detection of cancer, 2003. CA Cancer J Clin 2003;53(1):27-43
   PubMed Web of Science ®Google Scholar
• Winawer S, Fletcher R, Rex D, Colorectal cancer screening and surveillance: clinical guidelines and rationale-Update based on new evidence. Gastroenterology 2003;124(2):544-60
   PubMed Web of Science ®Google Scholar
• Lev D, Kotilingam D, Wei C, Optimizing treatment of desmoid tumors. J Clin Oncol 2007;25(13):1785-91
   PubMed Web of Science ®Google Scholar
• Patel SR, Benjamin RS. Desmoid tumors respond to chemotherapy: defying the dogma in oncology. J Clin Oncol 2006;24(1):11-2
   PubMed Web of Science ®Google Scholar
• Bussey HJ, DeCosse JJ, Deschner EE, A randomized trial of ascorbic acid in polyposis coli. Cancer 1982;50(7):1434-9
   PubMed Web of Science ®Google Scholar
• Waddell WR, Loughry RW. Sulindac for polyposis of the colon. J Surg Oncol 1983;24(1):83-7
   PubMed Web of Science ®Google Scholar
• Labayle D, Fischer D, Vielh P, Sulindac causes regression of rectal polyps in familial adenomatous polyposis. Gastroenterology 1991;101(3):635-9
   PubMed Web of Science ®Google Scholar
• Giardiello FM, Hamilton SR, Krush AJ, Treatment of colonic and rectal adenomas with sulindac in familial adenomatous polyposis. N Engl J Med 1993;328(18):1313-6
   PubMed Web of Science ®Google Scholar
• Cruz-Correa M, Hylind LM, Romans KE, Long-term treatment with sulindac in familial adenomatous polyposis: a prospective cohort study. Gastroenterology 2002;122(3):641-5
   PubMed Web of Science ®Google Scholar
• Winde G, Schmid KW, Schlegel W, Complete reversion and prevention of rectal adenomas in colectomized patients with familial adenomatous polyposis by rectal low-dose sulindac maintenance treatment. Advantages of a low-dose nonsteroidal anti-inflammatory drug regimen in reversing adenomas exceeding 33 months. Dis Colon Rectum 1995;38(8):813-30
   PubMed Web of Science ®Google Scholar
• Oshima M, Dinchuk JE, Kargman SL, Suppression of intestinal polyposis in Apc delta716 knockout mice by inhibition of cyclooxygenase 2 (COX-2). Cell 1996;87(5):803-9
   PubMed Web of Science ®Google Scholar
• Kawamori T, Rao CV, Seibert K, Reddy BS. Chemopreventive activity of celecoxib, a specific cyclooxygenase-2 inhibitor, against colon carcinogenesis. Cancer Res 1998;58(3):409-12
   PubMed Web of Science ®Google Scholar
• Chalada PC, Thompson MB, Mahler JF, Genetic disruption of Ptgs-1, as well as of Ptgs-2, reduces intestinal tumorigenesis in Min mice. Cancer Research 2000;60:4705-8
   PubMed Web of Science ®Google Scholar
• Kashfi K, Rigas B. Expanding the molecular target repertoire of chemoprevention. Biochemical Pharmacology 2005;70:969-86
   PubMed Web of Science ®Google Scholar
• Steinbach G, Lynch PM, Phillips RK, The effect of celecoxib, a cyclooxygenase-2 inhibitor, in familial adenomatous polyposis. N Engl J Med 2000;342(26):1946-52
   PubMed Web of Science ®Google Scholar
• Phillips RK, Wallace MH, Lynch PM, A randomised, double blind, placebo controlled study of celecoxib, a selective cyclooxygenase 2 inhibitor, on duodenal polyposis in familial adenomatous polyposis. Gut 2002;50(6):857-60
   PubMed Web of Science ®Google Scholar
• Hallak A, Alon-Baron L, Shamir R, Rofecoxib reduces polyp recurrence in familial polyposis. Dig Dis Sci 2003;48(10):1998-2002
   PubMed Web of Science ®Google Scholar
• Bresalier RS, Sandler RS, Quan H, Cardiovascular events associated with rofecoxib in a colorectal adenoma chemoprevention trial. N Engl J Med 2005;352(11):1092-102
   PubMed Web of Science ®Google Scholar
• Solomon SD, McMurray JJ, Pfeffer MA, Cardiovascular risk associated with celecoxib in a clinical trial for colorectal adenoma prevention. N Engl J Med 2005;352(11):1071-80
   PubMed Web of Science ®Google Scholar
• Piazza GA, Alberts DS, Hixson LJ, Sulindac sulfone inhibits azoxymethane-induced colon carcinogenesis in rats without reducing prostaglandin levels. Cancer Research 1997;57:2909-15
   PubMed Web of Science ®Google Scholar
• Thomson WJ, Piazza GA, Li H, Exisulind induction of apoptosis involves guanosine 3′,5′, -cyclic monophosphate phosphodiesterase inhibition, protein kinase G activation, and attentuated B-catenin. Cancer Research 2000; 60:3338-42
   PubMed Web of Science ®Google Scholar
• van Stolk R, Stoner G, Hayton WL, Phase I trial of exisulind (sulindac sulfone, FGN-1) as a chemopreventive agent in patients with familial adenomatous polyposis. Clin Cancer Res 2000;6(1):78-89
   PubMed Web of Science ®Google Scholar
• Di Sario JA OM, Szabo A, Exisilind for duodenal adenoma in persons with familial adenomatous polyposis. Gastroenterology 2005;W970(P):A-567
   Google Scholar
• Arber N, Kuwada S, Leshno M, Sporadic adenomatous polyp regression with exisulind is effective but toxic: a randomised, double blind, placebo controlled, dose-response study. Gut 2006;55:367-73
   PubMed Web of Science ®Google Scholar
• Giardiello FM, Yang VW, Hylind LM, Primary chemoprevention of familial adenomatous polyposis with sulindac. N Engl J Med 2002;346(14):1054-9
   PubMed Web of Science ®Google Scholar
• Burn J, Chapman PD, Mathers J, The protocol for a European double-blind trial of aspirin and resistant starch in familial adenomatous polyposis: the CAPP study. Concerted Action Polyposis Prevention. Eur J Cancer 1995;31A(7-8):1385-6
   PubMed Web of Science ®Google Scholar
• Meyskens FL Jr, McLaren CE, Pelot D, Difluoromethylornithine plus sulindac for the prevention of sporadic colorectal adenomas: a randomized placebo-controlled, double-blind trial. Cancer Prev Res (Phila Pa) 2008;1(1):32-8
   PubMed Web of Science ®Google Scholar
• Perkins S, Verschoyle RD, Hill K, Chemopreventive efficacy and pharmacokinetics of curcumin in the min/+ mouse, a model of familial adenomatous polyposis. Cancer Epidemiol Biomarkers Prev 2002;11(6):535-40
   PubMed Web of Science ®Google Scholar
• Cruz-Correa M, Shoskes DA, Sanchez P, Combination treatment with curcumin and quercetin of adenomas in familial adenomatous polyposis. Clin Gastroenterol Hepatol 2006;4(8):1035-8
   PubMed Web of Science ®Google Scholar
• Ribic CM, Sargent DJ, Moore MJ, Tumor microsatellite-instability status as a predictor of benefit from fluorouracil-based adjuvant chemotherapy for colon cancer. N Engl J Med 2003;349(3):247-57
   PubMed Web of Science ®Google Scholar
• Jarvinen HJ, Mecklin JP, Sistonen P. Screening reduces colorectal cancer rate in families with hereditary nonpolyposis colorectal cancer. Gastroenterology 1995;108(5):1405-11
   PubMed Web of Science ®Google Scholar
• Mecklin JP, Aarnio M, Laara E, Development of colorectal tumors in colonoscopic surveillance in Lynch syndrome. Gastroenterology 2007;133(4):1093-8
   PubMed Web of Science ®Google Scholar
• Renkonen-Sinisalo L, Aarnio M, Mecklin JP, Jarvinen HJ. Surveillance improves survival of colorectal cancer in patients with hereditary nonpolyposis colorectal cancer. Cancer Detect Prev 2000;24(2):137-42
   PubMedGoogle Scholar
• Glebov OK, Rodriguez LM, Lynch P, Celecoxib treatment alters the gene expression profile of normal colonic mucosa. Cancer Epidemiol Biomarkers Prev 2006;15(7):1382-91
   PubMed Web of Science ®Google Scholar
• Burn J, Bishop T, Jukka-Pekka M, Effect of aspirin or resistant starch on colorectal neoplasia in the lynch syndrome. N Engl J Med 2008;359:2567-78
   PubMed Web of Science ®Google Scholar